{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:57:07Z","timestamp":1794434227412,"version":"4.9.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032300","name":"National Center for Toxicological Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020523","name":"United States Drug Enforcement Administration","doi-asserted-by":"publisher","award":["HHSF223201610079C"],"award-info":[{"award-number":["HHSF223201610079C"]}],"id":[{"id":"10.13039\/100020523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001364","name":"University of Florida Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01DA058018"],"award-info":[{"award-number":["R01DA058018"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110603","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:28:25Z","timestamp":1753511305000},"page":"110603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["In vitro and in vivo pharmacological characterization of fentanyl analogs"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-0750","authenticated-orcid":false,"given":"Samuel","family":"Obeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle R.","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L.C.","family":"Pallares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-6318","authenticated-orcid":false,"given":"Lance R.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-1593","authenticated-orcid":false,"given":"William E.","family":"Fantegrossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Hiranita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110603_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/bja\/85.4.533","article-title":"Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery","volume":"85","author":"Ahonen","year":"2000","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2025.110603_bib2","first-page":"63","article-title":"Pharmacologic therapy for acute pain","volume":"104","author":"Amaechi","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2025.110603_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110603_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00204-018-2330-9","volume":"93","author":"\u00c5strand","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/dta.2906","article-title":"Activation of the \u03bc\u2010opioid receptor by alicyclic fentanyls: changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure","volume":"13","author":"\u00c5strand","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2025.110603_bib6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2021.1169","article-title":"Continued increases in overdose deaths related to synthetic opioids: implications for clinical practice","volume":"325","author":"Baldwin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2025.110603_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bph.15580","article-title":"Understanding and countering opioid\u2010induced respiratory depression","volume":"180","author":"Bateman","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1460-9568.2003.02439.x","article-title":"Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1\/A2a double knockout mice","volume":"17","author":"Berrendero","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110603_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109020","article-title":"In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, ocfentanyl and furanylfentanyl","volume":"209","author":"Bilel","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110603_bib10","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.2174\/138161212803582469","article-title":"Non-analgesic effects of opioids: opioid-induced respiratory depression","volume":"18","author":"Boom","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2025.110603_bib11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-3565(25)21207-1","article-title":"Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys","volume":"279","author":"Butelman","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib12","series-title":"U.S. Overdose Deaths in 2021 Increased Half as Much as in 2020 \u2013 but are Still up 15%","year":"2021"},{"key":"10.1016\/j.neuropharm.2025.110603_bib13","series-title":"CDC, National Center for Health Statistics, Office of Communication","article-title":"U.S. overdose deaths decrease in 2023, first time since 2018","year":"2024"},{"key":"10.1016\/j.neuropharm.2025.110603_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0024-3205(93)90152-S","article-title":"The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine","volume":"52","author":"Chen","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110603_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0091-3057(76)90103-9","article-title":"Discriminative stimulus properties of fentanyl and morphine: tolerance and dependence","volume":"5","author":"Colpaert","year":"1976","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110603_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110603_bib17","series-title":"U.S. Drug Enforcement Administration Emergency Schedules all Illicit Fentanyls in an Effort to Reduce Overdose Deaths","year":"2018"},{"key":"10.1016\/j.neuropharm.2025.110603_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/bja\/58.9.950","article-title":"Pharmacokinetics of fentanyl during constant rate iv infusion for the relief of pain after surgery","volume":"58","author":"Duthie","year":"1986","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2025.110603_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0160-5402(86)90056-2","article-title":"A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys","volume":"15","author":"Dykstra","year":"1986","journal-title":"J. Pharmacol. Methods"},{"key":"10.1016\/j.neuropharm.2025.110603_bib20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/0306-3623(94)90181-3","article-title":"The influence of various experimental conditions on the expression of naloxone-induced withdrawal symptoms in mice","volume":"25","author":"El-Kadi","year":"1994","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197734","article-title":"Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking","volume":"13","author":"Ellis","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110603_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ajad.12230","article-title":"Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: a case report","volume":"24","author":"Fareed","year":"2015","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neuropharm.2025.110603_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108599","article-title":"Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: differential antagonism by naltrexone","volume":"221","author":"Flynn","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110603_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.lfs.2003.07.005","article-title":"The [35S] GTP\u03b3S binding assay: approaches and applications in pharmacology","volume":"74","author":"Harrison","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110603_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.123.002032","article-title":"Comparison of the \u03bc-Opioid receptor antagonists methocinnamox and naloxone to reverse and prevent the ventilatory depressant effects of fentanyl, carfentanil, 3-Methylfentanyl, and heroin in Male rats","volume":"391","author":"Hiranita","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u03bc-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110603_bib28","first-page":"502","article-title":"The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats","volume":"13","author":"Janssen","year":"1963","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.neuropharm.2025.110603_bib29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bph.15573","article-title":"The anomalous pharmacology of fentanyl","volume":"180","author":"Kelly","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0091-3057(01)00600-1","article-title":"Assessment of acute and chronic morphine dependence in Male and female mice","volume":"70","author":"Kest","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110603_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s42003-025-07630-x","article-title":"Dynamics of agonist-evoked opioid receptor activation revealed by FRET- and BRET-Based opioid receptor conformation sensors","volume":"8","author":"Kirchhofer","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.forsciint.2018.08.010","article-title":"High buprenorphine-related mortality is persistent in Finland","volume":"291","author":"Kriikku","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2025.110603_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108115","article-title":"Listed for Sale: analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket","volume":"213","author":"Lamy","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110603_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00894-019-3999-2","article-title":"Molecular dynamics of fentanyl bound to \u03bc-opioid receptor","volume":"25","author":"Lipi\u0144ski","year":"2019","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.neuropharm.2025.110603_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2023.101096","article-title":"Focus on fentanyl in females: sex and gender differences in the physiological and behavioral effects of fentanyl","volume":"71","author":"Little","year":"2023","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib36","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1021\/jacsau.1c00341","article-title":"Kinetics and mechanism of fentanyl dissociation from the mu-Opioid receptor","volume":"1","author":"Mahinthichaichan","year":"2021","journal-title":"JACS Au"},{"key":"10.1016\/j.neuropharm.2025.110603_bib37","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0028-3908(92)90051-P","article-title":"Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta-and kappa-selective opioid antagonists","volume":"31","author":"Maldonado","year":"1992","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110603_bib38","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.2696","article-title":"Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest","volume":"112","author":"Mann","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2025.110603_bib39","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0960-894X(00)00394-2","article-title":"The synthesis and preliminary pharmacological evaluation of 4-methyl fentanyl","volume":"10","author":"Mi\u0107ovi\u0107","year":"2000","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2025.110603_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-010-1946-0","article-title":"Lack of a rewarding effect and a locomotor-enhancing effect of the selective \u03bc-opioid receptor agonist amidino-TAPA","volume":"212","author":"Mizoguchi","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110603_bib41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","article-title":"Higher doses of naloxone are needed in the synthetic opioid era","volume":"14","author":"Moss","year":"2019","journal-title":"Subst. Abuse Treat. Prev. Pol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1369-1600.2011.00354.x","article-title":"Possible involvement of prolonging spinal \u03bc\u2010opioid receptor desensitization in the development of antihyperalgesic tolerance to \u03bc\u2010opioids under a neuropathic pain\u2010like state","volume":"18","author":"Narita","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib43","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/add.13027","article-title":"Naloxone\u2014Does over\u2010antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin\/opioid overdose","volume":"110","author":"Neale","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2025.110603_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02246449","article-title":"Effects of the Delta opioid agonist BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure","volume":"126","author":"Negus","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110603_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.120.000189","article-title":"Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for mu-opioid receptor and opioid-like behavioral effects in rats","volume":"376","author":"Obeng","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbr.2006.02.009","article-title":"Gender-and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice","volume":"170","author":"Papaleo","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110603_bib47","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1038\/npp.2008.8","article-title":"Disruption of the CRF2 receptor pathway decreases the somatic expression of opiate withdrawal","volume":"33","author":"Papaleo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110603_bib48","article-title":"Illicitly manufactured fentanyl entering the United States","volume":"13","author":"Pergolizzi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.neuropharm.2025.110603_bib49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J. Addiction Med."},{"key":"10.1016\/j.neuropharm.2025.110603_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0376-8716(91)90053-2","article-title":"Abuse liability studies of opioid agonist-antagonists in humans","volume":"28","author":"Preston","year":"1991","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110603_bib51","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/jpet.104.082966","article-title":"In vivo characterization of 6\u03b2-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice","volume":"313","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2009.04.011","article-title":"Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6","volume":"104","author":"Raehal","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110603_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.neuropharm.2025.110603_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-3565(25)30828-1","article-title":"Discriminative effects of morphine in the squirrel monkey","volume":"201","author":"Schaefer","year":"1977","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/jpet.109.152678","article-title":"The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity","volume":"330","author":"Sirohi","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib56","first-page":"651","article-title":"Quantitation of physical dependence in mice by naloxone-precipitated jumping after a single dose of morphine","volume":"10","author":"Smits","year":"1975","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib57","series-title":"Statistical Methods","author":"Snedecor","year":"1967"},{"key":"10.1016\/j.neuropharm.2025.110603_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.5811\/westjem.2015.10.28454","article-title":"The changing use of intravenous opioids in an emergency department","volume":"16","author":"Sutter","year":"2015","journal-title":"West. J. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2025.110603_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110603_bib60","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1016\/S0021-9258(17)39198-6","article-title":"Why does coomassie brilliant blue R interact differently with different proteins? A partial answer","volume":"260","author":"Tal","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110603_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-3959(02)00041-6","article-title":"The interaction index: a measure of drug synergism","volume":"98","author":"Tallarida","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110603_bib62","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10550887.2010.509277","article-title":"Advanced urine toxicology testing","volume":"29","author":"Tenore","year":"2010","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neuropharm.2025.110603_bib63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.120.265561","article-title":"Fentanyl but not morphine interacts with nonopioid recombinant human neurotransmitter receptors and transporters","volume":"374","author":"Torralva","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib64","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0026-895X(25)08634-1","article-title":"Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells","volume":"47","author":"Traynor","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib65","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Culler\u00e9","year":"1999","journal-title":"Comp. Med."},{"key":"10.1016\/j.neuropharm.2025.110603_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/jpet.302.1.101","article-title":"Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine","volume":"302","author":"Walker","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)28247-7","article-title":"Simultaneous quantitative assessment of morphine tolerance and physical dependence","volume":"167","author":"Way","year":"1969","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110603_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.403","article-title":"Evaluation of morphine\u2010like effects of the mixed Mu\/Delta agonist morphine\u20106\u2010O\u2010sulfate in rats: drug discrimination and physical dependence","volume":"6","author":"Yadlapalli","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.neuropharm.2025.110603_bib70","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110603_bib71","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/0024-3205(95)02204-V","article-title":"Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding","volume":"57","author":"Zernig","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110603_bib72","article-title":"Locomotor activity: a distinctive index in morphine self-administration in rats","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:10:36Z","timestamp":1780027836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":71,"alternative-id":["S0028390825003119"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110603","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo pharmacological characterization of fentanyl analogs","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110603"}}